Table 1.
Patients’ characteristics
| Total number of patients | 25 |
| • Liver metastasectomy | 16 (64%) |
| • Lung metastasectomy | 9 (36%) |
| Age | |
| • Mean (SEM) | 58.5 (±2.26) |
| • Median (range) | 57 (40-87) |
| Gender | Females: 10 (40%), males: 15 (60%) |
| Location of primary tumor | |
| • rectosigmoid | 16 (64%) |
| • descending colon | 2 (8%) |
| • right colon/cecum | 7 (28%) |
| Synchronous vs. metachronous metastases | 10 (40%) vs. 15 (60%) |
| Neoadjuvant chemotherapy before metastasectomy | 16/25 (64%) |
| pT stage of primary tumor (data available in 20/25 (80%) patients) | |
| • pT1 | 2 (10%) |
| • pT2 | 3 (15%) |
| • pT3 | 10 (50%) |
| • pT4 | 5 (25%) |
| Lymph node status of the primary colorectal tumor N- vs. N+ (data available in 20/25 (80%) patients) | 8 (40%) vs. 12 (60%) |
| CEA serum level (ng/ml) (data available in 24/25 (96%) patients) | |
| • Mean (SEM) | 132.4 (±75.8) |
| • Median (range) | 5.6 (1.0-1437.0) |
| CA19.9 serum level (U/ml) (data available in 7/25 (28%) patients) | |
| • Mean (SEM) | 126.2 (±101.5) |
| • Median (range) | 40.0 (1.0-734.0) |
| Microsatellite instability (MSI-H and MSI-L) | 2/9 (22.2%) |
| KRAS mutation (codon 12 or 13) | 6/16 (37.5%) |
| BRAF mutation (codon 600) | 0/8 (0%) |
| Liver metastasectomy | 16 |
| • Resection | 10 (62.5%) |
| • Radiofrequency ablation (RFA) | 1 (6.3%) |
| • Resection & RFA | 5 (31.2%) |
| Lung metastasectomy | 9 |
| • Resection | 9 (100%) |
| EpCAM protein expression of resected metastases (n) | |
| Staining intensity (score 0-3) | 25 |
| • Mean (SEM) | 2.48 (±0.13) |
| • Median (range) | 3 (1-3) |
| Percentage (%) of positive cancer cells | |
| • Mean (SEM) | 69.6% (±23.89) |
| • Median (range) | 70.0% (20-100%) |